Aclaris Therapeutics (NASDAQ:ACRS) Rating Increased to Buy at BTIG Research

Aclaris Therapeutics (NASDAQ:ACRS - Get Free Report) was upgraded by research analysts at BTIG Research from a "neutral" rating to a "buy" rating in a note issued to investors on Tuesday, MarketBeat Ratings reports. The firm currently has a $8.00 price target on the biotechnology company's stock. BTIG Research's price target suggests a potential upside of 74.29% from the stock's previous close.

ACRS has been the topic of a number of other research reports. HC Wainwright reiterated a "neutral" rating on shares of Aclaris Therapeutics in a report on Tuesday, September 17th. StockNews.com upgraded Aclaris Therapeutics from a "sell" rating to a "hold" rating in a research note on Friday. Finally, Piper Sandler upgraded Aclaris Therapeutics from a "neutral" rating to an "overweight" rating and boosted their target price for the company from $3.00 to $13.00 in a research note on Monday. Three research analysts have rated the stock with a hold rating and four have given a buy rating to the stock. According to MarketBeat, Aclaris Therapeutics has a consensus rating of "Moderate Buy" and a consensus target price of $8.80.

Aclaris Therapeutics Stock Up 46.2 %

Shares of Aclaris Therapeutics stock traded up $1.45 during trading on Tuesday, hitting $4.59. The stock had a trading volume of 56,339,600 shares, compared to its average volume of 1,380,479. Aclaris Therapeutics has a 1 year low of $0.77 and a 1 year high of $5.17. The stock has a 50 day simple moving average of $1.53 and a 200 day simple moving average of $1.32. The company has a market capitalization of $327.86 million, a PE ratio of -7.73 and a beta of 0.10.

Aclaris Therapeutics (NASDAQ:ACRS - Get Free Report) last posted its quarterly earnings data on Wednesday, November 6th. The biotechnology company reported ($0.11) earnings per share for the quarter, missing the consensus estimate of ($0.08) by ($0.03). Aclaris Therapeutics had a negative return on equity of 40.26% and a negative net margin of 136.65%. The firm had revenue of $4.35 million for the quarter, compared to analysts' expectations of $8.31 million. As a group, equities analysts expect that Aclaris Therapeutics will post -0.65 earnings per share for the current fiscal year.

Institutional Trading of Aclaris Therapeutics

Institutional investors and hedge funds have recently made changes to their positions in the stock. SG Americas Securities LLC lifted its position in shares of Aclaris Therapeutics by 69.5% in the first quarter. SG Americas Securities LLC now owns 32,843 shares of the biotechnology company's stock worth $41,000 after buying an additional 13,461 shares during the last quarter. Russell Investments Group Ltd. lifted its position in shares of Aclaris Therapeutics by 5,265.1% in the first quarter. Russell Investments Group Ltd. now owns 62,772 shares of the biotechnology company's stock worth $78,000 after buying an additional 61,602 shares during the last quarter. Point72 Asia Singapore Pte. Ltd. acquired a new stake in shares of Aclaris Therapeutics in the second quarter worth about $119,000. Assenagon Asset Management S.A. acquired a new stake in shares of Aclaris Therapeutics in the third quarter worth about $214,000. Finally, BNP Paribas Financial Markets lifted its position in shares of Aclaris Therapeutics by 10.9% in the first quarter. BNP Paribas Financial Markets now owns 241,101 shares of the biotechnology company's stock worth $299,000 after buying an additional 23,747 shares during the last quarter. Institutional investors and hedge funds own 98.34% of the company's stock.

Aclaris Therapeutics Company Profile

Aclaris Therapeutics, Inc a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States. The company operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing therapies to address significant unmet needs for immuno-inflammatory diseases.